LymPro White Paper - Reimbursement & use of MAC 8.

New Post Public Reply Private Reply Replies (0) Message Board
SurfBandito redspeed #14322
LymPro White Paper - Reimbursement & use of MAC

8. Reimbursement Strategy

http://webcache.googleusercontent.com/search?...&gl=us

8.1 United States

There are three main components to reimbursement for diagnostics in the US: (i) coverage, (ii) coding, and (iii) pricing and payment.

8.1.1 Coverage

For payers, the decision whether or not to pay for (cover) a particular diagnostic product is generally driven by evaluation of the clinical evidence supporting the clinical utility of the test. That is the degree to which patient health outcomes are improved with the use of the test, and more importantly for the payers, evidence to support the net economic benefits provided by the improved outcomes. A recent exception is in the case of a companion diagnostic, one that is required for the safe and effective use of a particular therapeutic product; private payers have accepted inclusion of language to that effect in the drug label in lieu of the standard clinical utility data package. (It should be noted however that most of the patients likely to be tested with the LymPro test will be under the jurisdiction of Medicare (the older than 65 years population). Medicare’s coverage policies in particular tend to be more population based rather than individual benefit in their evidentiary review.

It is likely that the LymPro test will be ready for launch in a CLIA lab setting prior to the approval as a companion diagnostic of a companion therapeutic product. This means that Amarantus will likely need to undertake the studies necessary to provide the “reasonable and necessary” clinical evidence to support positive decisions by the payers, in particular Medicare.

These studies need to:

> Validate the test in terms of its analytical performance (sensitivity, specificity and reproducibility, limits of detection etc) across a range of patients who would meet the inclusion criteria for the test

> Confirm the diagnostic accuracy (or clinical validity) of the LymPro test with Alzheimer’s disease or other pre-specified Intended Use populations

> Document the clinical utility (i.e. reduction in costs or improvements in medical outcomes as a result of receiving additional information from the test)

> Provide evidence of the health economic impact of those clinical outcomes

> In addition many payers are now requesting evidence that physicians are changing their clinical interventions on the basis of the test results.

The good news about launching the test via a CLIA lab model is that despite the individual origins of the patient samples, all the billing will be conducted through a single Medicare Administrative Contractor or MAC . The medical director at the MAC wields significant power in the decision about whether or not to “cover” a test. Finding a knowledgeable medical director that is willing and able to review the evidence dossier is key, and consequently locating the CLIA lab in a jurisdiction with a diagnostically savvy medical director is prudent.

The good news is that by virtue of a “local coverage decision” by the regional MAC, a de facto “national coverage decision” for Medicare patients is obtained. Key influences on payers are peer reviewed papers that cover analytical performance (analytical validity), clinical performance (clinical validity) and clinical utility. Positive technology assessment reports provided by various groups such as the Blue Cross Blue Shield Association Technology Evaluation Center (TEC) and ICER at the Massachusetts General Hospital’s Institute for Technology Assessment are also exceedingly helpful. These reports provide a rigorous assessment of the clinical evidence and assess whether or not the technology improves outcomes such as, quality of life and ability to function. These Technology Assessment groups do not evaluate costs. The criteria that these groups use to review and assess published trial results are well documented and will be a key input to designing our clinical trial plans.

It will also be important to generate and publish data from the Clinical Utility studies that assess the health economic impact of the changes in outcomes resulting from use of the LymPro test. Modeling the data to reflect the characteristics of the individual health plan will be an important component for approaching and educating the medical directors of the payer plans that influence or directly write policies for coverage.

Prior to the availability of these data, Amarantus can generate theoretical models based upon current testing paradigms and previously published literature reflecting patient/physician behavior. These models in combination with published performance data can be used to educate and contract with select private payers (especially single payer systems like Kaiser, Geisinger), hopefully generating favorable coverage policies on a plan-by-plan basis.

It should be noted that in the absence of a disease modifying therapy, generating positive health economic outcomes, clinical outcomes evidence for the LymPro test as “an aid to diagnosis of dementia of the Alzheimer’s type” will be challenging. However, the Company should also evaluate cost reduction scenarios which may include the potential of a positive LymPro test result to shorten the “diagnostic odyssey.”

8.1.2 Coding

Amarantus intends to pursue the issuance of a Current Procedural Terminology (or CPT) procedure code specifically for the LymPro Test. The strategy will be to initially use a miscellaneous code and negotiate directly with payers for payment of submitted claims until a specific code is issued. This process generally takes 12-18 months through the AMA and would likely result in a temporary (assuming Amarantus could show reasonable utilization data) CPT code. In this case there is no obvious “under the radar strategy” since none of the existing flow cytometry codes will match the ICD9/10 Diagnostic codes for dementia of the Alzheimer type (331.0). In any case the LymPro Test is sufficiently different from existing CPT flow codes that matching the vignette would also be a stretch. Eventually with more clinical evidence, a national or permanent Tier 1 code could be established.
Figure 12. Process for healthcare reimbursement.

8.1.3 Pricing & Payment

Pricing levels will initially be negotiated directly with the payers based upon a dossier of information, that may include the following: i) cost analysis of resources required to perform the test (both fixed and variable); ii) amortization of the R&D investment to develop the test; iii) payment amounts determined by other payers; iv) a health economic model reflecting the performance of the LymPro test; v) charges, payment amounts and resources required for tests that may be comparable (crosswalk to other flow cytometry type test) or otherwise relevant (i.e. gap fill to an imaging tests such as Avid Radiopharmaceutical’s (now Lilly’s) Amyvid with an estimated $3,000-$5,000 per procedure in the US); and vi) projected test volume and utilization data. Because private payers often use Medicare as a benchmark when developing their own payment policies the outcome of the Medicare rate setting process could influence the payment rate set by other payers, consequently it is important to have a comprehensive strategy in place for commercialization of the test prior to engaging with the payers. Looking forward, it is anticipated that in the U.S. the emergence of a greater number of Managed Care & Accountable Care organizations will drive Rx/Dx combination pricing discussions.


Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 406

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 97

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 63

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 5

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 67

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding DraftKings Options Activity and Market Trends

Updated Category News Views 194

DraftKings: Analyzing Recent Options Activity In the world of financial trading, few stories capture attention quite like a company's options activity, especially when it comes to a prominent name such as DraftKings (NASDAQ: DKNG). Recently, significant bullish moves by major investors have been noted, illustrating a dynamic shift within the trading environment. Insights...

Continue Reading
Integrating Bitcoin into Modern Investment Strategies

Updated Category News Views 259

Why Bitcoin Is Essential in Today's Investment Landscape For many investors, Bitcoin remains a puzzling investment vehicle. A recent survey revealed that a significant portion of the population lacks confidence in the safety and reliability of cryptocurrencies. However, when industry leaders like BlackRock make statements regarding Bitcoin, it’s wise to take heed....

Continue Reading
Strengthening Global Ties: ICAC's Role in Combating Corruption

Updated Category News Views 240

Strengthening Global Ties: ICAC's Role in Combating Corruption In a significant development, the ICAC Commissioner Mr. Woo Ying-ming represented the International Association of Anti-Corruption Authorities (IAACA) at the G20 Anti-Corruption Working Group meeting, marking the first occasion for the ICAC to participate in such a global dialogue. The meeting brought together...

Continue Reading
FlexTV's New Release: A Drama of Love and Intrigue

Updated Category News Views 447

FlexTV Unveils English Adaptation of a Short Drama Mega Matrix Inc. (NYSE American: MPU) is thrilled to announce the premiere of its much-anticipated short drama Drink Me, Keep Me, Cut Me, now available in English on their streaming platform, FlexTV. This series offers viewers a tantalizing glimpse into the intricate relationship dynamics intertwined with love and...

Continue Reading
Canada Eases Mortgage Switch Process for Borrowers

Updated Category News Views 87

Canada's Mortgage Game-Changer: Easing Lender Switching In a bold move that could shake up the housing market, Canada’s banking regulator has rolled out a directive set to streamline how homeowners switch lenders during mortgage renewals. Finally! This change aims to chop through the red tape that often kept borrowers shackled to less favorable terms. The Short-Term...

Continue Reading